electronRx’s purpleDx turns a smartphone into a powerful medical tool
A new cardiopulmonary assessment app built to medical device standards developed by electronRX will be launched at CES 2025 from 7-10 January in Las Vegas.
The device, purpleDx, detects and monitors digital biomarkers to support health management and help improve therapeutic outcomes for chronic respiratory disease patients. With purpleDx, chronic respiratory disease (CRD) patients can detect and monitor digital biomarkers of lung function at home, while providing clinicians with real-time data to customise treatment plans and help improve patient outcomes.
The scalable technology utilises digital biomarkers generated from mobile device sensors that feed into high impact actionable clinical biomarkers to assess physiological cardiopulmonary metrics, such as heart rate, respiratory rate and tidal volume. Healthcare providers using the app-based platform can access the physiological data in real time via the clinical dashboard, enabling them to monitor patients’ lung function remotely and adjust treatment plans accordingly to help optimise drug efficacy. Remote monitoring also ensures patients need only travel to the hospital when necessary, saving them time and energy as well as helping to streamline healthcare delivery.
CRDs are the third leading cause of death, globally: since 2017, electronRx’s proprietary suite of digital solutions has been dedicated to improving the lives of people with breathing disorders using smartphone technology to measure changes in cardiac and pulmonary functions to support them in making informed interventions.
These digital apps are built onto the iPhone and use the camera to capture and measure the blood flow around the face that is invisible to the human eye. A typical 30-60 second measurement captures millions of data points that can then be converted into digital biomarkers to capture a range of physiological measurements.
Dr Bipin Patel, CEO and founder, electronRx, said: “Integrating digital biomarker monitoring with prescribed medications embodies a revolutionary approach to healthcare management. Our purpleDx technology transforms a mobile phone into a powerful tool.
“We’re incorporating the latest clinical insights and data into purpleDx to ensure our platform remains at the forefront of technological innovation and continues to drive advancements in the management and treatment of CRDs worldwide.
“We are incredibly grateful to all of our collaborators, particularly the patients, for their support and look forward to demonstrating electronRx’s purpleDx technology at CES next month.”
